These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 8623442)

  • 1. Deoxyspergualin: mechanism of action and pharmacokinetics.
    Ramos EL; Nadler SG; Grasela DM; Kelley SL
    Transplant Proc; 1996 Apr; 28(2):873-5. PubMed ID: 8623442
    [No Abstract]   [Full Text] [Related]  

  • 2. [15+/-deoxyspergualin, hope for patients with multiple sclerosis?].
    Kappos L; Theobald K; Hartung HP
    Nervenarzt; 1992 Dec; 63(12):768-71; discussion 772. PubMed ID: 1494394
    [No Abstract]   [Full Text] [Related]  

  • 3. Effects of 15-deoxyspergualin on mononuclear cells from kidney recipients.
    Johansson-Borg A; Ohlman S; Groth CG
    Transplant Proc; 1992 Feb; 24(1):267-8. PubMed ID: 1539276
    [No Abstract]   [Full Text] [Related]  

  • 4. Local immunosuppression of canine renal allografts with 15-deoxyspergualin.
    Hughes SE; Xiao S; Perera S; Fluno C; Hasselbarth J; Jayasankar V; Singh J; Del Rosario A; Freed BM; Singh TP; Lempert N; Conti DJ; Gruber SA
    Transplant Proc; 1996 Aug; 28(4):2054-5. PubMed ID: 8769153
    [No Abstract]   [Full Text] [Related]  

  • 5. 15-Deoxyspergualin: a newly developed immunosuppressive agent and its mechanism of action and clinical effect: a review. Japan Collaborative Transplant Study Group for NKT-01.
    Amemiya H
    Artif Organs; 1996 Aug; 20(8):832-5. PubMed ID: 8853792
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Deoxyspergualin. Mechanism of action studies of a novel immunosuppressive drug.
    Tepper MA
    Ann N Y Acad Sci; 1993 Nov; 696():123-32. PubMed ID: 8109823
    [No Abstract]   [Full Text] [Related]  

  • 7. Suppression of human anti-mouse antibody response to murine monoclonal antibody L6 by deoxyspergualin: a phase I study.
    Dhingra K; Fritsche H; Murray JL; LoBuglio AF; Khazaeli MB; Kelley S; Tepper M; Greene D; Booser D; Buzdar A
    Adv Exp Med Biol; 1994; 353():193-202. PubMed ID: 7985538
    [No Abstract]   [Full Text] [Related]  

  • 8. Immunosuppressive mechanisms and action of deoxyspergualin in experimental and clinical studies. Japanese Collaborative Transplant Study Group of NKT-01.
    Amemiya H
    Transplant Proc; 1995 Feb; 27(1):31-2. PubMed ID: 7879015
    [No Abstract]   [Full Text] [Related]  

  • 9. FK506 and deoxyspergualin: experimental studies and clinical applications.
    Suzuki S
    Transpl Immunol; 1994 Sep; 2(3):190-8. PubMed ID: 7528087
    [No Abstract]   [Full Text] [Related]  

  • 10. Elucidating the mechanism of action of the immunosuppressant 15-deoxyspergualin.
    Nadler SG; Eversole AC; Tepper MA; Cleaveland JS
    Ther Drug Monit; 1995 Dec; 17(6):700-3. PubMed ID: 8588244
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of 15-deoxyspergualin on antibody secretion by specific isotypes producing B-cell hybridomas and myelomas.
    Sterbenz KG; Tepper MA
    Transplant Proc; 1994 Dec; 26(6):3218-20. PubMed ID: 7998121
    [No Abstract]   [Full Text] [Related]  

  • 12. Inhibition of antibody production by the immunosuppressive agent, 15-deoxyspergualin.
    Tepper MA; Petty B; Bursuker I; Pasternak RD; Cleaveland J; Spitalny GL; Schacter B
    Transplant Proc; 1991 Feb; 23(1 Pt 1):328-31. PubMed ID: 1990547
    [No Abstract]   [Full Text] [Related]  

  • 13. Immunohistology of nonrejected deoxyspergualin-treated rat renal allografts.
    Kerr PG; Marshall VC; Atkins RC
    Transplant Proc; 1989 Oct; 21(5):3767-8. PubMed ID: 2815273
    [No Abstract]   [Full Text] [Related]  

  • 14. Flow cytometric analysis of graft-infiltrating lymphocytes in deoxyspergualin-treated rat renal transplants.
    Takeuchi I; Chikaraishi T; Kanagawa K; Tanda K; Seki T; Togashi M; Koyanagi T
    Transplant Proc; 1994 Aug; 26(4):1905-6. PubMed ID: 8066620
    [No Abstract]   [Full Text] [Related]  

  • 15. The immunosuppressant LF 15-0195 prevents experimental autoimmune myasthenia gravis in Brown-Norway rats.
    Duplan V; Dutartre P; Druet P; Saoudi A
    Transplant Proc; 2002 Nov; 34(7):2962-5. PubMed ID: 12431673
    [No Abstract]   [Full Text] [Related]  

  • 16. Use of a novel immunosuppressive agent, deoxyspergualin, in a case of ABO-incompatible kidney transplantation.
    Takahasi K; Ota K; Ooba S; Tanabe K; Fuchinoue S; Honda H; Teraoka S; Toma H; Agishi T; Amemiya H
    Clin Transpl; 1989; ():306-7. PubMed ID: 2487584
    [No Abstract]   [Full Text] [Related]  

  • 17. Stability and immunosuppressive activity of deoxyspergualin in comparison with deoxymethylspergualin.
    Fujii H; Takada T; Nemoto K; Abe F; Takeuchi T
    Transplant Proc; 1989 Jun; 21(3):3471-3. PubMed ID: 2525828
    [No Abstract]   [Full Text] [Related]  

  • 18. Suppressor cells induced by donor-specific transfusion and deoxyspergualin in cardiac xenografts from hamsters to rats.
    Valdivia LA; Wonden W; Gotoh M; Tono T; Nakano Y; Okamura J; Mori T
    Transplant Proc; 1991 Feb; 23(1 Pt 1):203-4. PubMed ID: 1824975
    [No Abstract]   [Full Text] [Related]  

  • 19. Deoxyspergualin--a different and intriguing immunosuppressant.
    Tufveson G; Gannedahl G
    Transplant Proc; 1994 Oct; 26(5):3029-39. PubMed ID: 7940954
    [No Abstract]   [Full Text] [Related]  

  • 20. Down-regulation of xenophile antibodies by 15-deoxyspergualin in an experimental animal model.
    Ulrichs K; Wang H; Müller-Ruchholtz W
    Transplant Proc; 1994 Apr; 26(2):994-6. PubMed ID: 8171724
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.